If you have already registered, please check your email for the webinar link.

Using Lab Automation to Treat Clinically Aggressive Cancers

Triple negative breast cancer is a clinically aggressive subtype of breast cancer with a high rate of drug resistance and few clinically approved targeted therapies. Moreover, traditional two-dimensional cell culture is unable to fully replicate the complexity of in vivo conditions during drug screens, making it an unreliable predictor for success in clinical trials.

Therefore, there is a critical need to develop laboratory models of triple negative breast cancer with greater clinical relevance. This can be accomplished through the use of three-dimensional patient-derived spheroids. Patient-derived models provide substantial advantages: they maintain the cellular heterogeneity of tumors as well as the complex stroma. Additionally, three-dimensional culture techniques which generate spheriods maintain important characteristics found in vivo, such as cell-cell interactions.

The Burow/Collins-Burow laboratory has characterized and generated a library of patient-derived xenografts (PDXs) and patient-derived cell lines (PDCs) generated from donated tissue from breast cancer patients in New Orleans. PDXs and PDCs can be used to generate three-dimensional culture models, including organoids and spheroids. Through using these models rather than immortalized cell lines, studies will have higher relevance to in vivo models and greater clinical relevance.

OnDemand Video Icon


Available On Demand


Brad Droubay.jpg
Courtney Brock
MD/PhD Student
Tulane University School of Medicine’s Physician-Scientist Program
Brad Droubay.jpg
Oksana Sirenko
Senior Scientist
Molecular Devices

Register Now!

You must have Javascript and Cookies enabled to access this webcast.